Analysts Issue Forecasts for Aclarion Q1 Earnings

Aclarion, Inc. (NASDAQ:ACON) – Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for Aclarion in a research note issued to investors on Thursday, May 28th. Ascendiant Capital Markets analyst L. Ward anticipates that the company will post earnings per share of ($1.51) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $7.50 price target on the stock. The consensus estimate for Aclarion’s current full-year earnings is ($4.37) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q2 2027 earnings at ($1.30) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($1.36) EPS and FY2027 earnings at ($5.37) EPS.

Several other research analysts also recently weighed in on the company. Weiss Ratings upgraded Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Wall Street Zen upgraded Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.50.

Aclarion Price Performance

Shares of ACON stock opened at $3.50 on Wednesday. Aclarion has a 1-year low of $2.34 and a 1-year high of $12.03. The stock’s fifty day moving average price is $3.29 and its 200 day moving average price is $4.07. The company has a market cap of $8.62 million, a price-to-earnings ratio of -0.39 and a beta of 1.22.

Aclarion (NASDAQ:ACON) last announced its earnings results on Wednesday, May 13th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.21. Aclarion had a negative return on equity of 54.41% and a negative net margin of 10,320.51%.The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million.

Aclarion announced that its board has authorized a stock buyback plan on Wednesday, April 22nd that permits the company to buyback $2.50 million in outstanding shares. This buyback authorization permits the company to reacquire up to 31% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.